

Special Issue

Novel Immunotherapies for Diffuse Large B-Cell Lymphoma

Message from the Guest Editor

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, characterized by remarkable biological heterogeneity and diverse clinical outcomes. Although standard immunochemotherapy regimens such as R-CHOP have improved survival, a significant proportion of patients experience relapse or refractory disease, underscoring the urgent need for innovative therapeutic strategies. Advances in CAR-T cell therapies, bispecific antibodies, immune checkpoint inhibitors, and antibody–drug conjugates have demonstrated promising efficacy in relapsed/refractory DLBCL. At the same time, insights from genomic, transcriptomic, and tumor microenvironment studies are guiding the development of more precise immune-based interventions. This Special Issue will bring together cutting-edge original research, comprehensive reviews, and translational insights that explore new immunotherapeutic avenues. We invite contributions spanning molecular mechanisms, preclinical models, biomarker discovery, and translational applications, with the goal of advancing precision medicine and improving patient outcomes in DLBCL.

Guest Editor

Dr. Waseem Lone

Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, USA

Deadline for manuscript submissions

20 March 2026



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/255113

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).